Loading…
Chinese biopharma known for toripalimab, a PD-1 immuno-oncology antibody approved in China and the US.
Chinese biopharma known for toripalimab, a PD-1 immuno-oncology antibody approved in China and the US.
Earns from toripalimab sold in China, where national insurance reimbursement widens access at lower prices, and from licence income: Coherus sells it in the US as Loqtorzi and makes upfront and milestone payments to Junshi under a 2021 agreement.
In one line: A Chinese Bristol Myers Squibb-style oncology immunotherapy developer.
Moat: narrow (IP / patents, regulatory licence). First Chinese-developed PD-1 approved by FDA; patent-protected antibody.
Headquarters: Shanghai, China · Founded: 2012 · Employees: 2,903
Size Shanghai Junshi Biosciences (1877.HK) is a Hong Kong Health Care company (Pharmaceuticals: Major) with a market value of $4.08B, the 293rd largest of 891 Hong Kong companies the cockpit tracks. Shares closed at HK$15.69 on 6 Nov 2026.
Performance Over six months the shares fell 38.7%, against +5.3% for the median peer and -13.4% for the Hong Kong market (cap-weighted) — lowest of 21 in its peer set.
Growth Revenue grew 35.8% over the last twelve months (peer median +5.4%); the operating margin is -14.3% (peer median 19.2%).
Valuation It trades at 9.6× enterprise value to sales against a peer median of 3.5× (3rd most expensive of 18).
Capital Return on invested capital runs 10.5 points below its cost of capital (8.4% WACC).
Next results Next results expected around 1 Apr 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | HK$3.65B | HK$2.70B | HK$2.11B | HK$1.66B | HK$1.69B |
| Revenue growth | — | +28% | +27% | -2% | — |
| Gross profit | HK$3.12B | HK$1.96B | HK$1.42B | HK$789M | HK$835M |
| EBITDA | n/a | -HK$667M | -HK$1.09B | -HK$2.41B | -HK$2.85B |
| Net income | -HK$480M | -HK$949M | -HK$1.39B | -HK$2.52B | -HK$2.78B |
| Free cash flow | -HK$848M | -HK$1.35B | -HK$2.25B | -HK$3.02B | -HK$2.46B |
| Capital expenditure | HK$901M | HK$833M | HK$749M | HK$920M | HK$458M |
| Total debt | HK$7.98B | HK$4.61B | HK$3.12B | HK$1.97B | HK$1.48B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Shanghai Junshi Biosciences 1877.HK | $4.08B | -39% | +36% | -14% | 9.6× | n/a |
| Innovent Biologics 1801.HK | $19.2B | -5% | +43% | 17% | 7.4× | 11.7% |
| Akeso 9926.HK | $10.2B | -38% | +42% | -25% | 19.5× | n/a |
| Bristol Myers Squibb BMY | $127B | +12% | +4% | 33% | 3.2× | -12.9% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 1877.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -12.3% | +6.9% | 3rd lowest of 21 |
| 6-month return | -38.7% | +5.3% | lowest of 21 |
| Distance from 52-week high | -49.1% | -20.0% | 3rd lowest of 21 |
| Revenue growth (TTM) | +35.8% | +5.4% | 4th highest of 20 |
| Operating margin | -14.3% | 19.2% | lowest of 18 |
| EV / Sales | 9.6× | 3.5× | 3rd most expensive of 18 |
| ROIC minus cost of capital | -10.5 pp | +7.9 pp | 2nd lowest of 18 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Shanghai Junshi Biosciences 1877.HK | Hong Kong | $4.08B | -39% | +36% | -14% | 9.6× | n/a | n/a |
| HUBEI JUMPCAN PHARMACEUTICAL 600566.SS | China | $4.05B | +6% | -4% | 32% | 2.8× | -11.5% | +0.3% |
| Yuhan 000100.KS | South Korea | $4.05B | -12% | +5% | 5% | 2.4× | 20.2% | +6.2% |
| Tianjin Pharmaceutical Da Ren Tang 600329.SS | China | $4.11B | +4% | -13% | 20% | 5.6× | 17.8% | -5.8% |
| Siegfried SFZN.SW | Switzerland | $3.98B | -10% | +4% | 16% | 3.0× | n/a | n/a |
| Liquidia LQDA | United States | $3.97B | +5% | +2,234% | 37% | 8.6× | 0.7% | +192.5% |
| Laboratorios Farmaceuticos Rovi ROVI.MC | Spain | $3.89B | +15% | +3% | 20% | 4.5× | 1.5% | +12.1% |
| Zhejiang Huahai Pharmaceutical 600521.SS | China | $3.86B | +8% | +10% | 12% | 3.4× | 7.3% | +5.9% |
| Santen Pharmaceutical 4536.T | Japan | $3.86B | +17% | -1% | 16% | 1.9× | -5.2% | +3.2% |
| HanmiPharm 128940.KS | South Korea | $4.36B | +2% | +14% | 16% | 3.5× | 5.0% | +7.5% |
| Ajanta Pharma AJANTPHARM.NS | India | $4.37B | +7% | +25% | 25% | 6.6× | 23.8% | +13.8% |
| Xenon Pharmaceuticals XENE | United States | $3.79B | +4% | -100% | n/a | n/a | n/a | n/a |
| China Resources Pharmaceutical 3320.HK | Hong Kong | $3.74B | -11% | +8% | 4% | 0.6× | -5.3% | +7.8% |
| Apeloa Pharmaceutical 000739.SZ | China | $3.73B | +18% | -16% | 10% | 2.8× | 6.3% | +4.5% |
| Definium Therapeutics DFTX | United States | $4.47B | +51% | n/a | n/a | n/a | n/a | n/a |
| Sunshine Guojian Pharmaceutical (Shanghai) 688336.SS | China | $4.47B | -34% | +227% | 74% | 6.5× | 3.3% | +45.1% |
| Emcure Pharmaceuticals EMCURE.NS | India | $4.47B | +33% | +21% | 16% | 4.3× | 14.9% | +12.7% |
| Livzon Pharmaceutical 000513.SZ | China | $3.71B | -4% | -14% | 19% | 2.2× | -9.8% | +2.7% |
| Amylyx Pharmaceuticals AMLX | United States | $3.70B | +97% | +100% | n/a | n/a | n/a | n/a |
| Camurus CAMX.ST | Sweden | $4.52B | +47% | 0% | 37% | 17.8× | 10.4% | +46.5% |
| GlaxoSmithKline Pharmaceuticals GLAXO.NS | India | $4.53B | +2% | +12% | 33% | 9.8× | 25.2% | +5.5% |